OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Morris on Findings From the TheraP Study in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Dr. Burgess on the Integration of PARP Inhibitors in Prostate Cancer

August 19th 2021

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Dr. Monk on the Utility of PARP Inhibitors as Frontline Maintenance in Ovarian Cancer

August 19th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Dr. Grisham on the Rationale for Binimetinib in Low-Grade Serous Ovarian Cancer

August 19th 2021

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Dr. Kumar on the Future Directions With Pirtobrutinib in MCL

August 19th 2021

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

Dr. Abida on Data from the PROfound Study in mCRPC

August 19th 2021

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.

Dr. Morris on the Efficacy of 177Lu-PSMA-617 Plus Best SOC in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Dr. Scott on the Rationale to Evaluate GARD-Based Radiotherapy Dosing in Oncology

August 18th 2021

Jacob G. Scott, MD, DPhil, discusses the rationale to evaluate genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Patel on the Potential Utility of Elranatamab in Multiple Myeloma

August 18th 2021

Krina K. Patel, MD, MSc, discusses the potential utility of elranatamab in multiple myeloma.

Dr. Ansell on the Utility of Non–CAR T-Cell Therapies in Non-Hodgkin Lymphoma

August 18th 2021

Stephen M. Ansell, MD, PhD, discusses the utility of non–CAR T-cell therapy options in non-Hodgkin lymphoma.

Dr. Kumar on Addressing Unmet Needs in Mantle Cell Lymphoma

August 17th 2021

Anita Kumar, MD, discusses efforts made to address areas of unmet need in mantle cell lymphoma.

Dr. Extermann on Selecting Among Available CDK4/6 Inhibitors in HR+ Breast Cancer

August 16th 2021

Martine Extermann, MD, PhD, shares advice for selecting among the CDK4/6 available for the treatment of patients with hormone receptor–positive breast cancer.

Dr. Sam on Sequencing Tucatinib and Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 16th 2021

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Dr. Carey on the Updated Results of the PALOMA-3 Trial in HR+/HER2- Breast Cancer

August 16th 2021

Lisa A. Carey, MD, FASCO, discusses the updated results of the phase 3 PALOMA-3 trial in hormone receptor–positive, HER2-positive breast cancer.

Dr. O’Malley on the Utility of Chemoimmunotherapy in Ovarian Cancer

August 16th 2021

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

Dr. Khong on the Importance of BRCA Testing in Breast Cancer

August 16th 2021

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer.

Dr. Miller on the Characteristics of Clonal Hematopoiesis

August 16th 2021

Peter G. Miller, MD, PhD, discusses the characteristics of clonal hematopoiesis.

Dr. Abida on the Limitations of PARP Inhibitors in Prostate Cancer

August 16th 2021

Wassim Abida, MD, PhD, discusses the limitations of PARP inhibitors in prostate cancer.

Dr. Martin on the Importance of Designing Clinical Trials for Real-World Utility in MCL

August 16th 2021

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

Dr. Kumar on Navigating CAR T-Cell Therapy–Related Toxicities in MCL

August 13th 2021

Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.